FY2025 · ended Dec 31, 2025 · Revenue $85.21M, +230194.6% YoY · Filed Mar 18, 2026
4D Molecular Therapeutics, Inc. (FDMT) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $85.2 million and a net loss of $140.1 million. Free cash flow was -$109.6 million. As of Jun 30, 2026 it held $430.6 million in cash and investments and $39.2 million in total debt.
Revenue (TTM)
$92.01M
+278712.1% vs year-ago TTM
Net income (TTM)
$-179.18M
+8.7% vs year-ago TTM
Operating cash flow (TTM)
$-156.07M
+6.2% vs year-ago TTM
Free cash flow (TTM)
$-156.18M
+8.0% vs year-ago TTM
EPS (TTM)
$-2.78
+21.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
57.61M
+25.8% vs prior year
Net cash
$391.41M
as of Jun 30, 2026
Operating margin
-214.2%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FDMT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1650648
- Former names
- 4D Molecular Therapeutics Inc. (until May 12, 2022); 4D Molecular Therapeutics Inc (until Sep 30, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $85.2M | $37,000 | $20.7M | $3.1M | $18.0M |
| Operating income | -$159.5M | -$187.8M | -$112.9M | -$110.0M | -$71.3M |
| Net income | -$140.1M | -$160.9M | -$100.8M | -$107.5M | -$71.3M |
| Diluted EPS | -$2.42 | -$2.98 | -$2.58 | -$3.32 | — |
| Operating cash flow | -$109.1M | -$134.6M | -$75.8M | -$86.7M | -$69.1M |
| Free cash flow | -$109.6M | -$138.4M | -$78.6M | -$98.2M | -$78.2M |
| Total assets | $566.7M | $560.4M | $339.9M | $261.8M | $353.5M |
| Total liabilities | $61.0M | $49.8M | $32.1M | $30.5M | $34.4M |
| Stockholders' equity | $505.7M | $510.6M | $307.8M | $231.3M | $319.1M |
| Cash and investments | $514.0M | $505.5M | $299.2M | $218.5M | $315.4M |
| Total debt | $21.4M | $24.6M | $14.7M | $16.1M | $16.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 28, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Other events
|
Jul 20, 2026 | Jul 18, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 29, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 17, 2026 |
All 439 4D Molecular Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.